SSY GROUP (02005) announced that its Bilastine and Sodium Picosulfate have been approved by China's National Medical Products Administration (NMPA) for registration as active pharmaceutical ingredients (APIs) in marketed preparations. Bilastine is primarily used for symptomatic treatment of urticaria, while Sodium Picosulfate is mainly indicated for bowel cleansing prior to surgical examinations such as colonoscopy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments